Co-Authors
This is a "connection" page, showing publications co-authored by Peter Johnson and Hala Chaaban.
Connection Strength
0.805
-
Inhaled Tobramycin Usage in Critically Ill Pediatric Patients Without Cystic Fibrosis: A Pediatric Pharmacy-Association, Practice-Based Research Network Survey Study. J Pediatr Pharmacol Ther. 2025 Jun; 30(3):332-339.
Score: 0.243
-
Detectable Concentrations With Inhaled Tobramycin in Critically Ill Infants and Children Following Implementation of Standardized Protocol. Ann Pharmacother. 2024 Sep 28; 10600280241282433.
Score: 0.232
-
Detectable Concentrations of Inhaled Tobramycin in Critically Ill Children Without Cystic Fibrosis: Should Routine Monitoring Be Recommended? Pediatr Crit Care Med. 2017 Dec; 18(12):e615-e620.
Score: 0.144
-
Impact of Ceftazidime Use on Susceptibility Patterns in a Neonatal Intensive Care Unit: A 7.5-year Evaluation. J Pediatric Infect Dis Soc. 2022 07 21; 11(7):349-350.
Score: 0.050
-
Evaluation of Ceftazidime Use in the Neonatal Intensive Care Unit and Association With Cephalosporin-Resistant Gram-Negative Bacteria. Ann Pharmacother. 2022 Dec; 56(12):1325-1332.
Score: 0.049
-
A Pilot Evaluation of the Possible Association of Metronidazole With Neurodevelopmental Outcomes in Premature Neonates. J Pediatr Pharmacol Ther. 2021; 26(5):455-459.
Score: 0.046
-
Impact of Ceftazidime Use on Susceptibility Patterns in the Neonatal Intensive Care Unit. Pediatr Infect Dis J. 2019 06; 38(6):605-607.
Score: 0.040